Migraine Clinical Trials 2024

Migraine Clinical Trials 2024

Migraine research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in migraine clinical trials today.

Trials for MA Patients

Trials for Headache Patients

Phase 3 Trials

Trials With No Placebo

View More Related Trials

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to migraine

What are the top hospitals conducting migraine research?

When it comes to cutting-edge research and clinical trials for migraine, several top hospitals are leading the way. In Bellevue, Washington, the Northwest Clinical Research Center stands out with an impressive 12 ongoing migraine trials and a total of 37 completed trials in their history. This facility has been dedicated to studying migraines since recording its first trial in 2014. Meanwhile, Clinvest Research LLC in Springfield is making significant contributions as well with nine active migraine trials and a previous record of 17 conducted studies since initiating their inaugural trial in 2018.

Moving east to Cincinnati, Ohio, the Cincinnati Children's Hospital Medical Center is at the forefront of pediatric migraine research. With eight ongoing clinical trials focused on migraines and a total of 13 previously conducted studies since their first recorded trial in 2012, this hospital plays a critical role in advancing our understanding of this condition among children.

In Stamford, Connecticut, the New England Institute for Clinical Research is actively involved in investigating new treatments for migraines. They currently have eight active migraine trials underway and have completed a commendable sixteen studies since conducting their initial trial also back in 2012.

Not far away from Stamford lies Boston Clinical Trials where another group of medical professionals are diligently working on finding solutions for those affected by migraines. With eight ongoing clinical trials and twenty-three completed investigations under their belt dating back to their first recorded trial in 2015,

All these hospitals demonstrate dedication towards unraveling mysteries surrounding migraines through cutting-edge research approaches across different regions within the United States.With every step forward taken by these esteemed institutions brings us closer toward advancements that could potentially transform countless lives affected by this debilitating condition worldwide

Which are the best cities for migraine clinical trials?

When it comes to migraine clinical trials, several cities have emerged as hubs for cutting-edge research. Miami, Florida leads the pack with 45 active trials investigating promising treatments such as Lasmiditan, Ubrogepant, and Rimegepant / BHV3000. Cincinnati, Ohio closely follows with 38 ongoing studies exploring treatments like Rimegepant / BHV3000, Ubrogepant, and Fremanezumab. Amherst, New york also plays a significant role in migraine research with 26 active trials focusing on therapies such as Fremanezumab, Eptinezumab, and Rimegepant / BHV3000. These cities offer individuals suffering from migraines access to state-of-the-art clinical trials that pave the way for improved treatment options and quality of life.

Which are the top treatments for migraine being explored in clinical trials?

The field of migraine treatment is constantly evolving, and clinical trials are at the forefront of exploring new possibilities. Eptinezumab has emerged as a top contender with four active trials and 12 all-time migraine trials since its introduction in 2019. Fremanezumab is also proving promising, currently being tested in three ongoing trials following its listing in 2016. Additionally, Emotional Awareness and Expression Therapy (EAET) shows potential with two active trials slated for this innovative approach introduced recently in 2023. Rimegepant / BHV3000 rounds out the list with two active trials examining its effectiveness against migraines since being listed in 2021. As research progresses, these treatments offer hope for improved management and relief from the debilitating effects of migraines.

What are the most recent clinical trials for migraine?

Exciting advancements in migraine treatment have emerged from recent clinical trials. One of them involves atogepant, which has shown promise in Phase 3 trials as a potential therapy for migraines. Additionally, ReMMiD-C Therapeutic Arm A and eptinezumab 300 mg have both demonstrated positive results in Phase 3 trials, offering hope for improved migraine management. Another trial focused on the use of greater occipital nerve blocks to alleviate migraines shows encouraging potential during its Phase 2 stage. These findings provide renewed optimism for individuals seeking effective solutions to manage their migraines and improve their quality of life.

What migraine clinical trials were recently completed?

Several recent clinical trials have made significant strides in the field of migraine treatment. March 2022 saw the completion of a trial sponsored by Allergan, which investigated the effectiveness of Ubrogepant. In December 2021, Eli Lilly and Company concluded their study on Galcanezumab, while H. Lundbeck A/S wrapped up their trial on Lu AG09222 in November 2021. Other completed trials include Dihydroergotamine (June and September 2021), Fremanezumab-Vfrm (December 2020), THC ~5% and CBD ~12% (November 2020), LY3451838 (November 2020), Erenumab-Aooe (October 2020) – all with various sponsors ranging from pharmaceutical companies to academic institutions. These advancements offer hope for individuals living with migraines by expanding our understanding of potential treatments for this debilitating condition.